Bioventus Q3 revenue rises 3% but misses estimates
BVS•Bioventus’ third-quarter revenue rose 3% to $142.4 million, below the $149.46 million consensus estimate, while adjusted EBITDA increased 7% to $28.4 million. The company updated 2026 net sales guidance to $590 million-$595 million and reaffirmed adjusted EPS guidance of $0.75-$0.79 per diluted share.
1. Quarterly results
Bioventus reported third-quarter revenue of $142.4 million, up 3% but below analyst expectations of $149.46 million. Adjusted EBITDA grew 7% to $28.4 million, which the company attributed to higher revenue and disciplined cost management, partially offset by increased investments.
2. 2026 outlook
The company updated its 2026 net sales guidance to $590 million-$595 million, representing growth of about 4%-5%. It reaffirmed adjusted EPS guidance of $0.75-$0.79 per diluted share and expects adjusted cash from operations of $84 million-$89 million.
3. Business trends
Revenue in Pain Treatments rose 6.2%, led by volume growth in hyaluronic acid therapy products, its PRP system and PNS products. Revenue in Restorative Therapies fell 3.4%, due to lower volume for the EXOGEN Bone Stimulation System. Bioventus continues to review potential strategic alternatives, as previously disclosed.
